"5-acetamido-2,6-Anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid"@en . . . "5-(acetylamino)-2,6-Anhydro-4-carbamimidamido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid"@en . . . "ZANAMIVIR"@en . . . . . "GNA"@en . . . . "Manjinder Singh Phull, Rajendra Narayanrao Kankan, Dharmaraj Ramachandra Rao, Ashwini Amol Sawant, Sanoj Thoppil, \"Process for Preparing Zanamivir and Intermediates for Use in the Process.\" U.S. Patent US20110257418, issued October 20, 2011."@en . "2.5-5.1 hours"@en . "GANA"@en . . "Zanamivir has limited plasma protein binding (<10%)."@en . . . "Influenza A virus"@en . . . . . . . . . . . . . . . . . . . . . . "(2R,3R,4S)-3-(acetylamino)-4-Carbamimidamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid"@en . . . . . "Zanamivir"@en . "For the prevention and treatment of influenza A and B."@en . "Zanamavir"@en . "The proposed mechanism of action of zanamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. By binding and inhibiting the neuraminidase protein, the drug renders the influenza virus unable to escape its host cell and infect others."@en . "ZMR"@en . "* 2.5 - 10.9 L/h [Following oral inhalation 10 mg] * 5.3 L/h [Normal renal function receiving IV single dose of 4 mg or 2 mg] * 2.7 L/h [Patients with mild and moderate renal impairement receiving IV single dose of 4 mg or 2 mg] * 0.8 L/h [Patients with severe renal impairement receiving IV single dose of 4 mg or 2 mg]"@en . "Relenza"@en . . "A guanido-neuraminic acid that is used to inhibit neuraminidase. [PubChem]"@en . . . . "Influenza B virus"@en . " "@en . "4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid"@en . "Absolute bioavailability is very low following oral administration (2%). Following oral inhalation, bioavailability is 4% to 17%."@en . . . . "investigational"@en . . . . . . "139110-80-8"@en . . . . . . . . . "4-Guanidino-neu5ac2en"@en . "Modified sialic acid"@en . "# Meindl P, Bodo G, Palese P, Schulman J, Tuppy H: Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology. 1974 Apr;58(2):457-63. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/4362431 # von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Van Phan T, Smythe ML, White HF, Oliver SW, et al.: Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993 Jun 3;363(6428):418-23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8502295 # Hata K, Koseki K, Yamaguchi K, Moriya S, Suzuki Y, Yingsakmongkon S, Hirai G, Sodeoka M, von Itzstein M, Miyagi T: Limited Inhibitory Effects of Oseltamivir and Zanamivir on Human Sialidases. Antimicrob Agents Chemother. 2008 Aug 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18694948 # Sugaya N, Tamura D, Yamazaki M, Ichikawa M, Kawakami C, Kawaoka Y, Mitamura K: Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis. 2008 Aug 1;47(3):339-45. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18582202"@en . "It is excreted unchanged in the urine with excretion of a single dose completed within 24 hours. Unabsorbed drug is excreted in the feces.Zanamivir is renally excreted as unchanged drug."@en . "approved"@en .